

37 **Abstract**

38 Hypertension during pregnancy increases the risk for adverse maternal and fetal outcomes, but
39 mechanisms of pregnancy hypertension are not precisely understood. Elevated plasma renin
40 activity and aldosterone concentrations play an important role in the normal physiologic
41 adaptation to pregnancy. These effectors are reduced in patients with pregnancy hypertension,
42 creating an opportunity to define features of the renin-angiotensin-aldosterone system (RAAS)
43 that are characteristic of this disorder. In the current study, we used a novel LC-MS/MS-based
44 methodology to develop comprehensive profiles of RAAS peptides and effectors over gestation
45 in a cohort of n=74 pregnant women followed prospectively for the development of gestational
46 hypertension and pre-eclampsia (HYP, n=27) versus remaining normotensive (NT, n=47). In NT
47 pregnancy, the plasma renin activity surrogate, (PRA-S, calculated from the sum of [angiotensin
48 I] + [angiotensin II] and aldosterone concentrations significantly increased from first to third
49 trimester, accompanied by a modest increase in concentrations of angiotensin peptide
50 metabolites. In contrast, in HYP pregnancies PRA-S and angiotensin peptides were largely
51 unchanged over gestation, and third trimester aldosterone concentrations were significantly
52 lower compared to NT pregnancies. Results indicate that the predominate features of
53 pregnancies that develop HYP are stalled or waning activation of the RAAS in the second half of
54 pregnancy (accompanied by unchanging levels of angiotensin peptides) and attenuated
55 secretion of aldosterone.

56

57

58 **Keywords:** angiotensin, maternal, pregnancy hypertension, biomarkers, mass spectrometry,
59 aldosterone

60

61

62 **1. Introduction**

63 New onset hypertension during pregnancy (gestational hypertension or pre-eclampsia) affects
64 5-10% of pregnancies, and the prevalence in the United States is rising[1]. Development of
65 hypertension during pregnancy is associated with long-term health risks for both the mother and
66 the offspring[2], and increases maternal risk for cardiovascular diseases later in life[3, 4].
67 Knowledge of mechanisms underlying perinatal hypertension could lead to improved strategies
68 for the treatment and/or management of hypertension during pregnancy [5, 6].

69 The renin angiotensin aldosterone system (RAAS) is a master regulator of blood
70 pressure and fluid homeostasis in pregnant and non-pregnant states[7, 8]. Activity of the RAAS
71 is initiated by the enzymatic cleavage of a ten-amino acid peptide, angiotensin I (Ang I) from the
72 N-terminus of angiotensinogen (AGT) by the enzyme renin in a highly regulated reaction. The
73 rate of Ang I formation in plasma, also called plasma renin activity (PRA), is determined by the
74 concentrations of active renin and AGT, where renin is rate-limiting. Ang I serves as a substrate
75 for angiotensin-converting enzyme (ACE), resulting in the formation of angiotensin II (Ang II),
76 the primary effector molecule of the RAAS. The concentration of active Ang II is controlled via
77 negative feedback on renin [9], and by metabolism at the n- or c-terminal by amino- and carboxy
78 peptidases in plasma, where the latter is considered to be a counter-regulatory arm of the
79 RAAS. Cleavage of Ang II by angiotensin-converting enzyme 2 (ACE2) generates angiotensin-
80 1-7(Ang 1-7)[10], a peptide with purported vasodilatory and other counter-effects to Ang II[11].

81 The classical effects of Ang II are mediated through the Ang II type 1 (AT₁) receptor, and
82 include vasoconstriction, activation of the sympathetic nervous system, and stimulation of
83 aldosterone release from the adrenal cortex[12, 13]. Outside of pregnancy, excess effects of
84 Ang II and aldosterone are associated with inflammation, fibrosis, and endothelial
85 dysfunction[14, 15], and abnormal function of the counter-regulatory arm of the RAAS has been
86 described in many cardiovascular [16, 17], renal[18], and infectious disease states(i.e. COVID-
87 19)[19].

88 In healthy pregnancy, there is pronounced activation of the RAAS, where PRA and
89 aldosterone concentrations are increased compared to non-pregnant states[20-22].
90 Upregulation of renin activity and aldosterone secretion play key roles in physiologic adaptations
91 to healthy pregnancy, such as promoting water and sodium reabsorption sufficient to support
92 the demand for a 40-50% expansion in blood volume[8, 23, 24]. In contrast, numerous studies
93 have demonstrated that pregnancies with pre-eclampsia or gestational hypertension have lower
94 plasma renin activity and lower aldosterone concentrations compared to normotensive
95 pregnancies. [21, 25-27]. Limited studies suggest the alternative RAAS may also play a role in
96 pregnancy, and that alterations in these components, e.g. Ang-1-7 and/or ACE2, are associated
97 with pre-eclampsia and small-for-gestational age infants[28-30]. The course of RAAS activity
98 over the course of gestation is not precisely understood in either normal or hypertensive
99 pregnancy[23, 31]. Understanding key deviations in the normal activity of the RAAS in
100 pregnancy could lead to improved detection or management of gestational hypertension and/or
101 pre-eclampsia.

102 RAS Fingerprint™ is novel, liquid chromatography-tandem mass spectrometry (LC-
103 MS/MS)-based methodology for simultaneous quantification of multiple components of the
104 RAAS in a single sample. Outside of pregnancy, recent studies have utilized RAS Fingerprint™
105 (or RAS profiling) to generate a biochemical “snapshot” of RAAS activity reflective of disease
106 state in patients with hypertension[32], heart failure[33, 34], and other diseases[35, 36]. In the
107 current study, we used RAS Fingerprint to quantify key effectors (angiotensin peptides and
108 aldosterone) of the RAAS in a cohort of women followed prospectively for the development of
109 gestational hypertension and pre-eclampsia. Our objective was to define prominent features of
110 RAAS activity associated with the development of pregnancy hypertension.

111

112

113 **2. Methods and Materials**

114 *Study Population*

115 This is a secondary analysis of n=74 pregnant individuals enrolled in an ongoing study at the
116 University of Kentucky. All subjects gave informed consent to participate in the study, which was
117 approved by the University of Kentucky Institutional Review Board, and all study
118 procedures/methods were performed in accordance with relevant guidelines and regulations.
119 The cohort is comprised of pregnant individuals without pre-pregnancy hypertension, but
120 otherwise meeting the following clinical risk factors for pre-eclampsia[37], where inclusion in the
121 study were more than one of the following clinical risk factors: history of preterm preeclampsia,
122 type 1 or 2 diabetes, renal or autoimmune disease; or more than two of the following clinical risk
123 factors: nulliparity, obesity (BMI > 30), family history of pre-eclampsia, Black race, lower income,
124 age 35 or older, previous pregnancy with small birth weight or adverse outcome, or in-vitro
125 conception. Patients not meeting these criteria were recruited as controls. Exclusion criteria
126 included age less than 18 or greater than 45 years, multifetal gestation, history of allergy to
127 aspirin, gastrointestinal bleeding, severe peptic ulcer or liver dysfunction, patients on
128 anticoagulant medications, and women with anomalous fetus.

129

130 *Study Design and Groups*

131 Pregnant women between 18 and 45 years of age in the first trimester of pregnancy were
132 recruited at the time of their routine prenatal visits or ultrasound appointments in the first
133 trimester screening and followed prospectively for the development of pre-eclampsia,
134 gestational hypertension, and related pregnancy outcomes. Patients were treated according to
135 standard clinical guidelines and data collected as part of routine clinical care. Demographic
136 information was collected upon enrollment. Clinical data and maternal blood were collected at
137 routine visits by trained study personnel at the first (11-16 weeks) and third (28-32 weeks)
138 trimesters of pregnancy, and outcomes were recorded at delivery. Blood pressure was

139 measured following the American Heart Association Guidelines[38], and was determined as the
140 average of two consecutive measurements per arm assessed in a seated, resting position by
141 one observer. Clinical data and outcomes were obtained from electronic medical records
142 (EMR), and input into a REDcap database by study personnel. Maternal blood was collected
143 into red-top serum tubes and rested at room temperature for 60 minutes followed by
144 centrifugation, transfer into 200 uL single-use aliquots, and barcoding. Samples were stored at -
145 80°C until analysis.

146 Development of pre-eclampsia or gestational hypertension was the primary endpoint.
147 Pregnancy outcomes were determined after delivery by trained clinical staff. Pre-eclampsia was
148 diagnosed according to guidelines by the American College of Gynecologists[39]: either systolic
149 blood pressure (SBP) or diastolic blood pressure (DBP) greater than 140 or 90 mmHg,
150 respectively, measured at least four hours apart after 20 weeks gestation, and one of the
151 following: proteinuria of 300 mg in 24 hours or a urine to protein creatinine ratio = 0.3, elevated
152 serum creatine greater than 1.1 mg/dL, liver function tests (AST/ALT) double the upper limits of
153 normal, platelet counts of <100,00/microliter, flash pulmonary edema, or neurologic features
154 including blurry vision or headaches not relieved with medication. Gestational hypertension was
155 diagnosed as either SBP or DBP greater than 140 or 90 mmHg, respectively, after 20 weeks
156 gestation in women with previously normal blood pressure[39]. The following adverse outcomes
157 were also recorded: gestational diabetes, small for gestational age (defined as fetal weight
158 below the 10th percentile), postpartum hemorrhage, preterm premature rupture of membranes
159 (PPROM), pre-term labor or pre-term delivery (<34 weeks), presence of polyhydramnios, or fetal
160 death.

161 In the current study, patients were grouped for analysis based on whether they met the
162 primary endpoint of either pre-eclampsia or gestational hypertension (HYP, n=27), or remained
163 normotensive (NT, n=47). We then investigated differences in measured serum components of

164 the RAAS over gestation (in the first versus third trimester) and at each time point among NT
165 and HYP groups.

166
167 *Quantification of angiotensin peptides, aldosterone, and equilibrium-based biomarkers PRA-S,*
168 *ACE-S, and the aldosterone to Ang II ratio (AA2-R) in serum using RAS Fingerprint™.*

169 Serum concentrations of six angiotensin peptides (Ang I, Ang II, Ang III, Ang IV, Ang-1-5, and
170 Ang-1-7) and aldosterone were quantified by LC-MS/MS following a controlled ex vivo
171 equilibration (i.e. equilibrium analysis) that has been previously described[40-43]. Equilibrium
172 analysis generates a “snapshot” of RAAS activity in a sample that reflects the biochemical
173 features of the circulating RAAS, based on the principle that all components required to
174 generate angiotensin metabolites in vivo are present in plasma. Briefly, serum samples were
175 incubated at 37 °C for one hour to generate a controlled equilibrium, followed by stabilization
176 through addition of an enzyme inhibitor cocktail. Samples were spiked with stable isotope-
177 labeled internal standards at 200 pg/mL for each angiotensin metabolite. The samples were
178 subjected to C-18-based solid-phase-extraction, followed by LC-MS/MS analysis using a
179 reversed-phase analytical column (Acquity UPLC C18, Waters, Milford, Massachusetts, USA)
180 operating in line with a Xevo TQ-S triple quadrupole mass spectrometer in multiple reaction
181 monitoring mode (Waters, Milford, Massachusetts, USA). Internal standards were used to
182 correct for peptide recovery of the sample preparation procedure for each analyte in each
183 individual sample. Analyte concentrations were determined using software
184 (MassLynx/Target/Lynx, Waters, Milford, Massachusetts, USA) via integration of the total ion
185 chromatogram obtained from a sum of quantifier transitions that have been optimized for
186 sensitivity and specificity, and integrated signals exceeded a signal-to noise ratio of 10. Analyte
187 concentrations were determined via linear calibration and reported in pmol/L. Batch
188 performance is evaluated based on calculated levels of calibrator and quality control samples
189 (must be within 15% of nominal concentration); lowest calibrator (lower limit of quantification –

190 LLOQ) must be within 20% of nominal concentration; at least 67% of all quality control and
191 calibrators must comply. The lower limits of quantification (LLOQs) for each peptide were:
192 angiotensin I: 5 pmol/L; angiotensin II: 4 pmol/L; angiotensin III: 4 pmol/L; angiotensin IV: 2
193 pmol/L; angiotensin-(1-5): 2 pmol/L; angiotensin-(1-7): 3 pmol/L, and aldosterone: 13 pmol/L.
194 For values below the LLOQ, means for each analyte and calculation of equilibrium-based
195 biomarkers were calculated using half the LLOQ[43].

196 Equilibrium concentrations of Ang I, Ang II, and aldosterone were used to calculate
197 biomarkers reflecting PRA, ACE activity, and the aldosterone to Ang II ratio (AA2-R), as
198 previously described[32, 41]. The plasma renin activity surrogate (PRA-S) was calculated from
199 the sum of the equilibrium concentrations of Ang I and Ang II ($[\text{eqAng I}] + [\text{eqAng II}]$) (pmol/L); the
200 surrogate for ACE activity (ACE-S) was calculated from the ratio of the equilibrium
201 concentrations of Ang II to Ang I ($[\text{eqAng II}] / [\text{eqAng I}]$) (pmol/L/pmol/L); the aldosterone to Ang
202 II ratio (AA2-R) was calculated by dividing aldosterone concentrations by equilibrium
203 concentrations of Ang II ($[\text{Aldosterone}] / [\text{eqAng II}]$) (pmol/L/pmol/L). PRA-S, ACE-S, and AA2-R
204 have been utilized as biomarkers of the RAAS that correlate with clinical parameters and/or
205 predict outcomes in numerous studies, including in humans with hypertension and/or primary
206 aldosteronism[32, 44-46], heart failure[33, 43, 47], COVID-19[48, 49], and others[50, 51].

207

208

209 *Statistical Analysis*

210 Statistical analyses were performed via GraphPad Prism version 9.5.1 (San Diego, CA, USA)
211 and SPSS Statistics version 24 (IBM, Armonk, NY). All data were assessed for normality, and
212 the appropriate parametric/nonparametric tests used. Clinical and demographic data were
213 analyzed for between-group differences (NT versus HYP), where continuous variables were
214 analyzed using paired t-tests, and categorical variables were analyzed using chi-square or
215 Fisher's exact test. For serum components of the RAAS, Mann-Whitney tests were applied for

216 between-groups analysis at each time point in independent samples, and within-group changes
217 from first to third trimester were determined using Wilcoxon matched-pairs signed rank tests. A
218 p-value less than 0.05 was considered statistically significant.

219

220

221 **3. Results**

222 *Subject characteristics.* Paired clinical data and biological samples from first and third trimester
223 visits were obtained for 74 women between April 2019 and May 2020. The cohort
224 demographics, clinical characteristics, and outcomes are described in Table 1. The cohort was
225 primarily Caucasian, with Black, Hispanic, and mixed-race individuals distributed fairly equally
226 among groups. The HYP group had a slightly greater risk profile compared to NT, with more
227 patients being primiparous, having a previous pre-eclamptic pregnancy, having type 1 diabetes,
228 and taking aspirin for the prevention of pre-eclampsia. The NT group contained slightly more
229 patients with type 2 diabetes, and with renal or autoimmune disease. First trimester BMI was
230 significantly greater in HYP compared to the NT, as was first and third trimester SBP and DBP,
231 although only four patients in the HYP received hypertension treatment. Duration of gestational
232 was significantly shorter in HYP versus NT groups.

233 The HYP group was comprised of twenty-three patients who developed gestational
234 hypertension and six patients that developed pre-eclampsia. Both NT and HYP patients
235 experienced adverse outcomes such as gestational diabetes, PPRM, polyhydramnios, and
236 postpartum hemorrhage. Slightly more HYP than NT patients developed gestational diabetes,
237 but no HYP patients had IUGR or pre-term labor/delivery, compared to two and three,
238 respectively, in the NT group.

239

240

241

242 **Table 1.** Patient demographics and clinical characteristics of women that developed gestational
 243 hypertension or pre-eclampsia (HYP) in pregnancy or remained normotensive (NT).

Parameter	NT N=47	HYP N=27
Patient Demographics, n (%)		
Race		
Caucasian	33 (70)	20 (74)
Black or African American	7 (15)	4 (15)
Hispanic	6 (13)	2 (7)
Asian	1 (2)	0
Mixed race	0	1 (4)
Primiparous	19 (40)	14 (52)
Previous pre-eclampsia	6 (13)	8 (30)
Type 1 DM	7 (15)	9 (33)
Type 2 DM	5 (11)	2 (7)
Renal disease	1 (2)	0
Autoimmune disease	7 (15)	0
Medications		
Aspirin	22 (47)	18 (67)
Labetalol or Nifedipine	0	4 (15)
Clinical Characteristics, mean \pm SD		
Age, years	30 \pm 6	28 \pm 6
BMI (1 st trimester), kg/m ²	29 \pm 7	32 \pm 8 [#]
SBP, mmHg		
1 st Trimester	113 \pm 11	122 \pm 9 ^{###}
3 rd Trimester	115 \pm 9	126 \pm 10 ^{####}
DBP, mmHg		
1 st Trimester	73 \pm 8	80 \pm 6 ^{###}
3 rd Trimester	73 \pm 6	81 \pm 6 ^{####}
Gestational age at delivery, weeks	38.6 \pm 1.5	36.8 \pm 1.6 ^{####}
Outcomes, n (%)		
Gestational hypertension	0	23 (85)
Pre-eclampsia	0	6 (22)
Gestational diabetes	3 (6)	4 (15)
PPROM	3 (6)	1 (4)
Polyhydramnios	4 (9)	2 (7)
IUGR	2 (5)	0
Pre-term labor or delivery	3 (6)	0
Postpartum hemorrhage	7 (15)	4 (15)

244 **Table 1. Demographics, clinical characteristics, and outcomes in NT and HYP**
 245 **pregnancies.** #, P<0.05; ###, P<0.001; ####, P<0.0001 analyzed by *t*-test.

246 *Attenuated activation of the classical RAAS over gestation in pregnancies that develop*
 247 *hypertension versus remaining normotensive.*
 248 We used RAS Fingerprint with equilibrium analysis to quantify angiotensin peptides, aldosterone
 249 concentrations, and biomarkers in serum of pregnant women in the first and third trimester of
 250 pregnancy. Table 2 list the median and IQR for all measured and calculated components of the
 251 RAAS in the cohort - in general, most components of the RAAS were significantly increased
 252 over gestation in NT, but not HYP, and tended to be lower in HYP versus NT in the third
 253 trimester.

254

255 **Table 2. Serum concentrations of RAAS components in normotensive (NT) and**
 256 **hypertensive (HYP) groups in the first and third trimesters of pregnancy.**

RAAS Component	NT N=47	HYP N=20	P value [®]
Ang I, pmol/L 1 st Trimester 3 rd Trimester	72.7 (45.9 – 112.1) 115.6 (69.2 – 172.7) ^{****}	61.6 (36.2 – 104.1) 71.6 (51.2 – 145.1)	0.645 0.080
Ang II, pmol/L 1 st Trimester 3 rd Trimester	165.3 (110.5 – 197.0) 180.9 (130.8 – 290.2) [*]	143.9 (76.3 – 211.7) 141.9 (87.8 – 244.5)	0.404 0.053
Ang III, pmol/L 1 st Trimester 3 rd Trimester	4.3 (2.0 – 9.2) 5.9 (2.0 – 10.1)	2.0 (2.0 – 7.3) 2.0 (2.0 – 4.9)	0.602 0.012
Ang IV, pmol/L 1 st Trimester 3 rd Trimester	8.6 (5.3 – 12.9) 10.1 (5.2 – 14.0)	5.8 (3.4 – 10.1) 7.4 (4.6 – 11.9)	0.107 0.149
Ang-1-5, pmol/L 1 st Trimester 3 rd Trimester	5.3 (3.4 – 7.8) 7.7 (5.3 – 10.9) ^{**}	4.3 (3.0 – 8.3) 5.2 (3.3 – 8.2)	0.571 0.084
Aldosterone, pmol/L 1 st Trimester 3 rd Trimester	386.1 (226.2 – 626.2) 970.5 (468.3 – 1586.0) ^{****}	290.2 (181.3 – 791.0) 492.5 (260.3 – 826.9)	0.680 0.003
PRA-S, pmol/L 1 st Trimester 3 rd Trimester	243.2 (157.5 – 309.1) 307.9 (214.7 – 474.8) ^{***}	194.3 (126.8 – 341.7) 223.7 (143.4 – 343.2)	0.426 0.067
ACE-S, pmol/L / pmol/L 1 st Trimester 3 rd Trimester	2.16 (1.83 – 2.98) 1.78 (1.30 – 2.08) ^{****}	2.27 (1.79 – 3.21) 1.83 (1.45 – 2.41) ^{**}	0.703 0.534
Aldosterone-Ang II ratio (AA2-R), pmol/L / pmol/L 1 st Trimester 3 rd Trimester	2.07 (1.63 – 3.33) 4.25 (3.20 – 7.71) ^{****}	2.25 (0.90 – 4.67) 3.38 (2.04 – 6.27)	0.929 0.161

257

258 **Table 2. Concentrations of angiotensin (Ang) peptides, aldosterone, and the biomarkers**

259 **PRA-S, ACE-S, and AA2-R at equilibrium determined by liquid chromatography with**

260 **tandem mass spectrometry (LC-MS/MS).** Data are median and interquartile range (IQR). @,

261 NT versus HYP within trimester, analyzed by Mann-Whitney test. *, P<0.05, **, P<0.01, ***,

262 P<0.001, ****, P<0.0001 for third trimester vs first trimester within group analyzed by Wilcoxon

263 signed rank test. Abbreviations: PRA-S: surrogate biomarker for plasma renin activity,

264 calculated from ([Ang I] + [Ang II]); ACE-S: surrogate biomarker for ACE activity, calculated from

265 ([Ang II] / [Ang I]).

266

267 As previous studies of pregnancy indicated that classical biomarkers for activation of the


268 RAAS, PRA (or direct renin concentration) and plasma aldosterone concentrations (PAC), are

269 reduced in gestational hypertension or pre-eclampsia[25, 27, 52], we examined PRA-S and

270 aldosterone concentrations generated using RAS Fingerprint in our cohort of NT and HYP

271 pregnancies (Figure 1). PRA-S was significantly increased from the first to third trimester in

272 pregnancies that remained NT ($P < 0.001$) with a median percent increase of 31% (Figure 1A,
273 1C). In contrast, PRA-S was not statistically increased in pregnancies that developed HYP



274 ($p=0.889$), and the median percent change in PRA-S over gestation in the HYP group was zero
275 (Figure 1A, 1C). Median values for PRA-S were not different between NT and HYP at either the
276 first or third trimester, although there was a trend toward a lower PRA-S in HYP versus NT in
277 the third trimester ($p=0.067$; Figure 1A, Table 2). Similarly, serum aldosterone concentrations
278 significantly increased over gestation in the NT group ($P < 0.0001$), with a median percent
279 increase of 135%. In HYP, aldosterone rose by 57%, although the change over gestation was
280 not significant ($p=0.141$), and third trimester concentrations of aldosterone were significantly
281 lower in HYP versus NT ($P < 0.01$; Figure 1B, 1D, Table 2).

282

283

284 **Figure 1. RAS Fingerprint-generated biomarkers for activation of the classical RAAS in**
285 **normotensive versus hypertensive pregnancy.** A) PRA-S, a surrogate for plasma activity
286 calculated from the sum of the equilibrium concentrations of Ang I and Ang II, and B)
287 aldosterone concentrations in the first and third trimesters of pregnancies that developed
288 hypertension after 20 weeks gestation (HYP, n=27) and those that remained normotensive (NT,
289 n=47). PRA-S and aldosterone levels were not different among NT and HYP in the first
290 trimester, but increased over gestation only in the group that remained NT. Data are median,
291 95th confidence intervals (CI). ***, $P<0.001$, and ****, $P<0.0001$ for within-group increase from
292 first to third trimester analyzed by Wilcoxon matched-pairs signed rank tests. ##, $P<0.01$
293 compared to NT using Mann-Whitney test. The percent change from first to third trimester in
294 C)PRA-S and D) aldosterone concentrations in NT and HYP patients. The percent increase
295 over gestation in PRA-S and aldosterone was significantly lower in pregnancies that developed
296 HYP compared to NT. Data are median, 95th CI of the percent change for each biomarker over
297 pregnancy in NT and HYP groups. #, $P<0.05$ compared to NT using Mann-Whitney test.

298


299

300 *Metabolism of Ang II and activation of the counter-regulatory RAAS in NT and HYP*
301 *pregnancies.*

302 We quantified angiotensin metabolites upstream (Ang I) and downstream (Ang III and Ang IV,
303 generated via n-terminal metabolism; and Ang-1-5 and Ang-1-7, generated via c-terminal
304 metabolism) from Ang II (Figure 2A-D, Table 2). In NT, Ang II concentrations were only
305 modestly increased across gestation ($P<0.05$), although Ang I formation was robustly increased
306 across pregnancy ($P<0.0001$; Figure 2A, 2B, Table 2). In the HYP group, Ang II concentrations
307 were not increased at all ($p=0.594$), but concentrations of Ang I were (non-significantly)

308 increased over gestation ($p=0.052$; Figure 2A, 2B, Table 2). There was a relative decrease in
309 Ang II to Ang I over gestation, reflected by a decrease in ACE-S, evident in both NT and HYP
310 groups (Table 2). There was a relative increase in aldosterone concentrations relative to Ang II
311 (AA2-R) over gestation in NT ($P<0.010$) but not HYP patients ($p=0.141$, Table 2).

312 Metabolism of Ang II was assessed by examining the concentrations of n- (sum of the
313 concentrations of Ang III and Ang IV) and c-terminal metabolites (sum of the concentrations of
314 Ang-1-5 and Ang-1-7), where c-terminal metabolites are reflective of activity of the counter-
315 regulatory arm of the RAAS[25]. Concentrations in pmol/L of n- and c-terminal metabolites of
316 Ang II were 10-fold lower than Ang II and Ang I concentrations in both NT and HYP groups
317 (Figure 2B, 2C, Table 2). Concentrations of Ang-1-7 were below the LLOQ in most patients in
318 the NT group (detected in only 7 and 16 patients in the first and third trimester, respectively),
319 and in the HYP group (detected in only 7 and 9 patients in the first and third trimester,
320 respectively), so median values with IQR for this analyte were less than the LLOQ and not listed
321 in Table 2. Half the value of the LLOQ (a concentration of 1.5 pmol/L) in those samples with
322 Ang-1-7 concentrations below the LLOQ was used to calculate the sum of c-terminal peptides.
323 The concentrations of c- and n-terminal metabolites were not different in NT versus HYP in the
324 first or third trimester (Figure 2C, 2D), but in the NT group, the concentration of c-terminal
325 metabolites significantly increased over gestation (Figure 2D).



326
327 **Figure 2. Equilibrium concentrations of Ang II, and upstream and downstream**
328 **angiotensin metabolites in normotensive and hypertensive pregnancy.** A) Ang II and B)
329 Ang I concentrations in the first and third trimester in NT (n=47) and HYP (n=27) groups. Data
330 are median with 95th confidence intervals (CI). *, P<0.01, ****, P<0.01, within-group increase
331 from first to third trimester analyzed by Wilcoxon matched-pairs signed rank tests. P=0.052
332 increase across gestation in HYP. C) The concentration of n-terminal metabolites of Ang II,
333 calculated from the sum of the concentrations of Ang III and Ang IV, and D) the concentration of
334 c-terminal metabolites of Ang II, calculated from the sum of the concentrations of Ang-1-5 and
335 Ang-1-7. Data are median with 95th CI. P=0.053, between group analysis at the third trimester

336 analyzed via Mann-Whitney. **, $P < 0.01$ within-group increase from first to third trimester

337 analyzed by Wilcoxon matched-pairs signed rank tests.

338

339 **4. Discussion**

340 Previous studies have demonstrated that the RAAS is suppressed in pregnancies with
341 pregnancy hypertension, but deviations in the activity of the RAAS compared to normotensive
342 pregnancy have not been comprehensively described. We used RAS Fingerprint to quantify
343 multiple angiotensin metabolites and biomarkers of the RAAS over gestation in pregnant women
344 with or without pregnancy hypertension. The main results from this study, the first to report LC-
345 MS/MS-based RAAS profiles in a prospective study of pregnancy hypertension, are 1) a marked
346 increase across gestation was evident in PRA-S, and especially aldosterone concentrations, in
347 NT pregnancy, but 2) not in those that developed HYP, where PRA-S was largely unchanged
348 after the first trimester of pregnancy, and third trimester aldosterone concentrations were
349 significantly lower than the NT group; 3) the increase in aldosterone secretion across gestation
350 was proportionally greater than the change in PRA-S or Ang II in both groups, with a more
351 robust effect in the NT group; and 4) c- and n-terminal metabolites, present in low
352 concentrations in both groups, generally increased over gestation in the NT but the HYP group.
353 Taken together, these findings indicate that normotensive pregnancy is associated with a
354 sustained increase in Ang I (and to a lesser degree, Ang II) concentrations over gestation,
355 accompanied by a marked elevation in aldosterone concentrations and moderate increase in
356 alternative RAAS metabolites. The predominate features of pregnancies that develop HYP are
357 stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by
358 unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone.

359 The comprehensive RAAS profiles generated in our study agree with previous studies
360 reporting low renin and aldosterone levels in normal and hypertensive pregnancy, and extend
361 them to include detailed activity of angiotensin peptide metabolites over gestation. PRA and

362 aldosterone concentrations are progressively increased with pregnancy, and can exceed non-
363 pregnant levels by 2-3 fold[26, 52]. PRA is increased early in gestation [53], where aldosterone
364 concentrations peak in the third trimester[54]. In pregnancies that develop hypertension, some
365 studies have shown that PRA is initially elevated as in normotensive pregnancy, but fails to
366 increase over gestation or decreases to non-pregnant levels[25]. Several studies have
367 demonstrated that, aldosterone concentrations, although reduced compared to normotensive,
368 still rise to some degree over pregnancy, even when PRA is declining[25, 26]. These studies are
369 consistent with our observations, where PRA-S and aldosterone increased over gestation only
370 in the NT group, but aldosterone remained elevated in in the HYP group. Our study did not
371 contain a non-pregnant group for comparison, but reported values of RAAS biomarkers in non-
372 pregnant cohorts generated with the same LC-MS/MS-based methodology are available. The
373 median and IQR reported for PRA-S and Ang II in a cohort of 77 individuals with hypertension
374 was 165.6 (80.6–328.3) pmol/L and 100.9 (56.3–227.0) pmol/L, respectively[32]. These values
375 are substantially lower than PRA-S and Ang II values reported here in the third trimester of the
376 HYP group, suggesting that RAAS activity was still higher compared to non-pregnant state.

377 Because pre-eclampsia is associated with lower plasma volume [54], suppression of the
378 RAAS is somewhat paradoxical. In longitudinal studies of pregnancies that developed
379 gestational hypertension or pre-eclampsia, downward trending of PRA levels over pregnancy
380 correlated with the onset of high blood pressure [25, 26, 55]. In our study, patients that
381 developed HYP failed to increase RAS components over pregnancy, and had generally lower
382 concentrations of angiotensin peptides in the third trimester. Downregulation of renin activity
383 with disease course suggests a compensatory response to high blood pressure[55], rather than
384 a primary event in the pathogenesis of the disease. An additional explanation for low activation
385 of the RAAS in hypertensive pregnancies could be reduced concentration or availability of
386 AGT[56], the substrate for renin. Langer et al previously made the observation that first trimester

387 Ang I levels were low compared to Ang II (similar to our study), and suggested that Ang II
388 synthesis was not limited by renin, but rather perhaps by AGT [52].

389 Historical studies by Gant et al demonstrate that normotensive pregnancies become
390 refractory to the pressor effects of Ang II, presumably for protection against vasoconstrictive
391 effects of Ang II, where pregnancies that develop hypertension progressively lose this response
392 over the second half of pregnancy [57]. This suggests factors impacting AT₁ receptor signaling
393 in pregnancy, such as presence or absence of AT₂ receptors[58], metabolic
394 derangements[34658252], or AT₁ autoantibody-binding might facilitate negative cellular effects
395 of Ang II (promotion of inflammation[59] or renal[60]), that lead to the progression of
396 hypertension. In our cohort, blood pressure was elevated in HYP compared to NT in the first
397 trimester, suggesting the presence of underlying vascular dysfunction in this group, potentially
398 caused by previous pre-eclampsia or type 1 diabetes exhibited in this group.

399 Factors contributing to aldosterone secretion in hypertensive pregnancy are complex.
400 Previous studies reported that aldosterone concentrations in pregnancy exceeded those
401 expected on the basis of renin levels[57]. In our study, aldosterone concentrations relative to
402 Ang II were significantly increased over gestation only in NT groups, but HYP pregnancies still
403 had elevated aldosterone compared to non-pregnant cohorts[32] in the second half of
404 pregnancy, despite no sustained activation of the RAAS. These data suggest non-Ang II
405 stimulation of aldosterone is a feature of both normotensive and hypertensive pregnancy, but
406 the possibility of altered sensitivity of AT₁ receptors to Ang II in the adrenal cortex in one group
407 compared to another is not excluded. Purported non-angiotensin stimulants of aldosterone in
408 pregnancy include ACTH, where ACTH stimulated aldosterone not only in normotensive but also
409 hypertensive pregnancies[61], and VEGF [62]. In pre-eclampsia, the presence of circulating
410 factors such as the VEGF receptor binding splice variant, sFlts-1, and AT₁-autoantibodies, may
411 impair aldosterone synthesis or release[63]. In addition, aldosterone concentrations could be
412 suppressed by excess sodium in pre-eclampsia resulting from activation of epithelial sodium

413 channels (ENaC)[64]. Notably, gain of function variants in aldosterone synthase (CYP11B2)
414 were preferably present in normotensive versus pre-eclamptic pregnancies, suggesting an
415 evolutionary basis for an active mineralocorticoid receptor system to protect against pre-
416 eclampsia[65].

417 Enhanced concentrations of Ang-1-7 were reported in normal pregnancy, and reduced
418 concentrations in pre-eclampsia, where authors hypothesized that Ang-1-7 may function in
419 healthy pregnancy to oppose potentially adverse (vasoconstrictive) effects of Ang II[29, 66].
420 Similarly, in a recent study, plasma Ang-(1-7) concentrations were elevated throughout
421 pregnancy compared to a non-pregnant control group, and reduced in preeclampsia[28],
422 suggesting a protective effect of ACE2 against hypertension during pregnancy via generation of
423 Ang-1-7. In contrast, we report limited detection of Ang-1-7 in NT and HYP patients (using mass
424 spectrometry, which is the gold standard for quantification of biological molecules and a major
425 strength of our study[67, 68]); in samples where Ang-1-7 was detected, concentrations were
426 significantly lower than those reported in other studies via radioimmunoassay[28, 29].
427 Discrepancies in reported values likely result from different methodologies used for the
428 detection of Ang-1-7, where cross-reactivity in antibody-based assays, (as peptide sequences
429 may only differ by one or two amino acids), may explain artificially high measured
430 concentrations of Ang-1-7[69]. Notably, reliability of ELISA for quantification of angiotensin-(1-7)
431 has recently been called into question[70]). Ang-1-5, a c-terminal metabolite of Ang-1-7, is
432 considered a component of the alternative RAAS[51, 71]. Ang-1-5 was readily detected in our
433 study by mass spectrometry, so we used the sum of Ang-1-7 and Ang-1-6 concentrations as an
434 indicator of the alternative RAAS. Concentration of Ang-1-7 + Ang-1-5 did increase over
435 gestation in NT, but not HYP pregnancies. However, concentrations of angiotensin metabolites
436 downstream from Ang II, (whether c- or n-terminally degraded), 10-fold less than the
437 concentrations of Ang II and Ang I. This data suggests the main bioactive effector of the RAAS

438 is Ang II, and that modulatory effects of Ang-1-7 in pregnancy are likely specific to local
439 tissues[72].

440 Our study has several limitations. We did not differentiate among pre-eclampsia and
441 gestational hypertension due to small numbers. Pre-eclampsia, especially, is a heterogenous
442 disease, where some subtypes may result from a different pathophysiology[6], with a different
443 RAAS profile. Also, our study did not control for sodium or volume status, which could affect
444 concentrations of aldosterone and PRA-S. Although previous studies have indicated that
445 sensitivity of renin and aldosterone to salt are blunted in pregnancy[57, 73], differences in salt
446 and aldosterone relationships in pregnancy hypertension versus normotensive are not well-
447 understood.

448

449 **5. Conclusions**

450 In summary, we sought to define prominent features of RAAS activity associated with the
451 development of pregnancy hypertension using a novel methodology for comprehensive
452 assessment of the RAAS. Concentrations of PRA-S, angiotensin peptides, and aldosterone
453 were not different among NT and HYP in the first trimester, significantly increased over
454 gestation only in the group that remained NT, and tended to be lower in the third trimester in
455 HYP compared to NT. We conclude that pregnancies that develop HYP are characterized by
456 stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by
457 unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone. Clinical
458 application of this knowledge may inform detection or treatment of pregnancy hypertension or
459 related adverse outcomes.

460

461 **Author contributions.** Study conception and design (JAB, JOB, AS); clinical data collection
462 (KV, AS, HH, CC); blood analysis of RAS and interpretation (RS, MP); analysis and
463 interpretation of results (RS, MP, AS, JAB, JOB); manuscript preparation (RS).

464 **Sources of funding.** The work was supported in part by a grant from the Kentucky BIRCWH
465 Program, NIDA 5K12DA035150 (RS) and by the Kentucky Children's Hospital Children's
466 Miracle Network Research Fund.

467 **Institutional Review Board Statement:** The study was conducted in accordance with the
468 Declaration of Helsinki, and approved by the Institutional Review Board at the University of
469 Kentucky. All study procedures/methods were performed in accordance with relevant guidelines
470 and regulations.

471 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the
472 study.

473 **Data availability.** Data may be made available by investigators upon reasonable request to
474 corresponding author: robin.shoemaker@uky.edu.

475 **Competing interests.** M. Poglitsch is an employee at Attoquant Diagnostics, a company
476 developing angiotensin-based biomarkers for hypertension. The other authors report no
477 conflicts.

478 **6. References**

- 479 1. Wen, T.; Schmidt, C. N.; Sobhani, N. C.; Guglielminotti, J.; Miller, E. C.; Sutton, D.; Lahtermaher,
480 Y.; D'Alton, M. E.; Friedman, A. M., Trends and outcomes for deliveries with hypertensive
481 disorders of pregnancy from 2000 to 2018: A repeated cross-sectional study. *BJOG* **2022**, 129,
482 (7), 1050-1060.
- 483 2. Alexander, B. T.; South, A. M.; August, P.; Bertagnolli, M.; Ferranti, E. P.; Grobe, J. L.; Jones, E. J.;
484 Loria, A. S.; Safdar, B.; Sequeira-Lopez, M. L. S.; American Heart Association Council on the
485 Kidney in Cardiovascular, D.; Council on, C.; Stroke, N.; Council on Cardiovascular, R.;
486 Intervention; Council on, H.; Council on, L.; Cardiometabolic, H., Appraising the Preclinical
487 Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of
488 Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward:
489 A Scientific Statement From the American Heart Association. *Hypertension* **2023**, 80, (5), e75-
490 e89.

- 491 3. Cirillo, P. M.; Cohn, B. A., Pregnancy complications and cardiovascular disease death: 50-year
492 follow-up of the Child Health and Development Studies pregnancy cohort. *Circulation* **2015**, 132,
493 (13), 1234-42.
- 494 4. Lo, C. C. W.; Lo, A. C. Q.; Leow, S. H.; Fisher, G.; Corker, B.; Batho, O.; Morris, B.; Chowaniec, M.;
495 Vladutiu, C. J.; Fraser, A.; Oliver-Williams, C., Future Cardiovascular Disease Risk for Women
496 With Gestational Hypertension: A Systematic Review and Meta-Analysis. *J Am Heart Assoc* **2020**,
497 9, (13), e013991.
- 498 5. Rana, S.; Lemoine, E.; Granger, J. P.; Karumanchi, S. A., Preeclampsia: Pathophysiology,
499 Challenges, and Perspectives. *Circ Res* **2019**, 124, (7), 1094-1112.
- 500 6. Society for Maternal-Fetal Medicine . Electronic address, p. s. o., Executive summary: Workshop
501 on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine
502 and the Preeclampsia Foundation. *Am J Obstet Gynecol* **2021**, 225, (3), B2-B7.
- 503 7. Wu, C. H.; Mohammadmoradi, S.; Chen, J. Z.; Sawada, H.; Daugherty, A.; Lu, H. S., Renin-
504 Angiotensin System and Cardiovascular Functions. *Arterioscler Thromb Vasc Biol* **2018**, 38, (7),
505 e108-e116.
- 506 8. Irani, R. A.; Xia, Y., The functional role of the renin-angiotensin system in pregnancy and
507 preeclampsia. *Placenta* **2008**, 29, (9), 763-71.
- 508 9. Johns, D. W.; Peach, M. J.; Gomez, R. A.; Inagami, T.; Carey, R. M., Angiotensin II regulates renin
509 gene expression. *Am J Physiol* **1990**, 259, (6 Pt 2), F882-7.
- 510 10. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.;
511 Hsieh, F.; Acton, S.; Patane, M.; Nichols, A.; Tummino, P., Hydrolysis of biological peptides by
512 human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* **2002**, 277, (17),
513 14838-43.
- 514 11. Ferrario, C. M.; Chappell, M. C.; Tallant, E. A.; Brosnihan, K. B.; Diz, D. I., Counterregulatory
515 actions of angiotensin-(1-7). *Hypertension* **1997**, 30, (3 Pt 2), 535-41.
- 516 12. Allen, A. M.; Zhuo, J.; Mendelsohn, F. A., Localization and function of angiotensin AT1 receptors.
517 *Am J Hypertens* **2000**, 13, (1 Pt 2), 31S-38S.
- 518 13. Forrester, S. J.; Booz, G. W.; Sigmund, C. D.; Coffman, T. M.; Kawai, T.; Rizzo, V.; Scalia, R.;
519 Eguchi, S., Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and
520 Pathophysiology. *Physiol Rev* **2018**, 98, (3), 1627-1738.
- 521 14. Montezano, A. C.; Nguyen Dinh Cat, A.; Rios, F. J.; Touyz, R. M., Angiotensin II and vascular
522 injury. *Curr Hypertens Rep* **2014**, 16, (6), 431.
- 523 15. Minas, J. N.; Thorwald, M. A.; Conte, D.; Vazquez-Medina, J. P.; Nishiyama, A.; Ortiz, R. M.,
524 Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in
525 angiotensin II-infused rats. *Clin Exp Pharmacol Physiol* **2015**, 42, (11), 1178-88.
- 526 16. Binder, C.; Poglitsch, M.; Agibetov, A.; Duca, F.; Zotter-Tufaro, C.; Nitsche, C.; Aschauer, S.;
527 Kammerlander, A. A.; Oetztuerk, B.; Hengstenberg, C.; Mascherbauer, J.; Bonderman, D., Angs
528 (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With
529 Heart Failure and Preserved Ejection Fraction. *Hypertension* **2019**, 74, (2), 285-294.
- 530 17. Ramchand, J.; Patel, S. K.; Kearney, L. G.; Matalanis, G.; Farouque, O.; Srivastava, P. M.; Burrell,
531 L. M., Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe
532 Myocardial Fibrosis. *JACC Cardiovasc Imaging* **2020**, 13, (3), 655-664.
- 533 18. Wong, D. W.; Oudit, G. Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q. C.; Backx, P. H.; Penninger, J. M.;
534 Herzenberg, A. M.; Scholey, J. W., Loss of angiotensin-converting enzyme-2 (Ace2) accelerates
535 diabetic kidney injury. *Am J Pathol* **2007**, 171, (2), 438-51.
- 536 19. Patel, S. K.; Juno, J. A.; Lee, W. S.; Wragg, K. M.; Hogarth, P. M.; Kent, S. J.; Burrell, L. M., Plasma
537 ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19
538 pathogenesis and consequences. *Eur Respir J* **2021**, 57, (5).

- 539 20. Weinberger, M. H.; Kramer, N. J.; Petersen, L. P.; Cleary, R. E.; Young, P. C., Sequential changes
540 in the renin--angiotensin--aldosterone systems and plasma progesterone concentration in
541 normal and abnormal human pregnancy. *Perspect Nephrol Hypertens* **1976**, 5, 263-9.
- 542 21. Brown, M. A.; Zammit, V. C.; Mitar, D. A.; Whitworth, J. A., Renin-aldosterone relationships in
543 pregnancy-induced hypertension. *Am J Hypertens* **1992**, 5, (6 Pt 1), 366-71.
- 544 22. Bentley-Lewis, R.; Graves, S. W.; Seely, E. W., The renin-aldosterone response to stimulation and
545 suppression during normal pregnancy. *Hypertens Pregnancy* **2005**, 24, (1), 1-16.
- 546 23. Verdonk, K.; Visser, W.; Van Den Meiracker, A. H.; Danser, A. H., The renin-angiotensin-
547 aldosterone system in pre-eclampsia: the delicate balance between good and bad. *Clin Sci*
548 *(Lond)* **2014**, 126, (8), 537-44.
- 549 24. Jensen, E.; Wood, C.; Keller-Wood, M., The normal increase in adrenal secretion during
550 pregnancy contributes to maternal volume expansion and fetal homeostasis. *J Soc Gynecol*
551 *Investig* **2002**, 9, (6), 362-71.
- 552 25. Tsai, Y. L.; Wu, S. J.; Chen, Y. M.; Hsieh, B. S., Changes in renin activity, aldosterone level and
553 electrolytes in pregnancy-induced hypertension. *J Formos Med Assoc* **1993**, 92, (6), 514-8.
- 554 26. Elsheikh, A.; Creatsas, G.; Mastorakos, G.; Milingos, S.; Loutradis, D.; Michalas, S., The renin-
555 aldosterone system during normal and hypertensive pregnancy. *Arch Gynecol Obstet* **2001**, 264,
556 (4), 182-5.
- 557 27. Zitouni, H.; Raguema, N.; Gannoun, M. B. A.; Hebert-Stutter, M.; Zouari, I.; Maleh, W.; Faleh, R.;
558 Letaifa, D. B.; Almawi, W. Y.; Fournier, T.; Mahjoub, T.; Guibourdenche, J., Impact of obesity on
559 the association of active renin and plasma aldosterone concentrations, and aldosterone-to-renin
560 ratio with preeclampsia. *Pregnancy Hypertens* **2018**, 14, 139-144.
- 561 28. Tamanna, S.; Clifton, V. L.; Rae, K.; van Helden, D. F.; Lumbers, E. R.; Pringle, K. G., Angiotensin
562 Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. *Front*
563 *Physiol* **2020**, 11, 590787.
- 564 29. Merrill, D. C.; Karoly, M.; Chen, K.; Ferrario, C. M.; Brosnihan, K. B., Angiotensin-(1-7) in normal
565 and preeclamptic pregnancy. *Endocrine* **2002**, 18, (3), 239-45.
- 566 30. Sykes, S. D.; Pringle, K. G.; Zhou, A.; Dekker, G. A.; Roberts, C. T.; Lumbers, E. R.; consortium, S.,
567 Fetal sex and the circulating renin-angiotensin system during early gestation in women who
568 later develop preeclampsia or gestational hypertension. *J Hum Hypertens* **2014**, 28, (2), 133-9.
- 569 31. J, J. S.; M, A. B., Renin-angiotensin system in pre-eclampsia: everything old is new again. *Obstet*
570 *Med* **2012**, 5, (4), 147-153.
- 571 32. Burrello, J.; Buffolo, F.; Domenig, O.; Tetti, M.; Pecori, A.; Monticone, S.; Poglitsch, M.; Mulatero,
572 P., Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary
573 Aldosteronism. *Hypertension* **2020**, 75, (1), 163-172.
- 574 33. Binder, C.; Poglitsch, M.; Duca, F.; Rettl, R.; Dachs, T. M.; Dalos, D.; Schrutka, L.; Seirer, B.; Ligios,
575 L. C.; Capelle, C.; Eslam, R. B.; Qin, H.; Hengstenberg, C.; Bonderman, D., Renin Feedback Is an
576 Independent Predictor of Outcome in HFpEF. *J Pers Med* **2021**, 11, (5).
- 577 34. Pavo, N.; Goliasch, G.; Wurm, R.; Novak, J.; Strunk, G.; Gyongyosi, M.; Poglitsch, M.; Saemann,
578 M. D.; Hulsmann, M., Low- and High-renin Heart Failure Phenotypes with Clinical Implications.
579 *Clin Chem* **2018**, 64, (3), 597-608.
- 580 35. Jha, S.; Taschler, U.; Domenig, O.; Poglitsch, M.; Bourgeois, B.; Pollheimer, M.; Pusch, L. M.;
581 Malovan, G.; Frank, S.; Madl, T.; Gruber, K.; Zimmermann, R.; Macheroux, P., Dipeptidyl
582 peptidase 3 modulates the renin-angiotensin system in mice. *J Biol Chem* **2020**, 295, (40), 13711-
583 13723.
- 584 36. Wolf, P.; Mayr, J.; Beiglbock, H.; Fellingner, P.; Winhofer, Y.; Poglitsch, M.; Gessl, A.; Kautzky-
585 Willer, A.; Luger, A.; Krebs, M., Identifying a disease-specific renin-angiotensin-aldosterone

- 586 system fingerprint in patients with primary adrenal insufficiency. *Eur J Endocrinol* **2019**, 181, (1),
587 39-44.
- 588 37. LeFevre, M. L.; Force, U. S. P. S. T., Low-dose aspirin use for the prevention of morbidity and
589 mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement.
590 *Ann Intern Med* **2014**, 161, (11), 819-26.
- 591 38. Pickering, T. G.; Hall, J. E.; Appel, L. J.; Falkner, B. E.; Graves, J. W.; Hill, M. N.; Jones, D. H.; Kurtz,
592 T.; Sheps, S. G.; Roccella, E. J.; Council on High Blood Pressure Research, P.; Public Education
593 Subcommittee, A. H. A., Recommendations for blood pressure measurement in humans: an AHA
594 scientific statement from the Council on High Blood Pressure Research Professional and Public
595 Education Subcommittee. *J Clin Hypertens (Greenwich)* **2005**, 7, (2), 102-9.
- 596 39. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'
597 Task Force on Hypertension in Pregnancy. *Obstet Gynecol* **2013**, 122, (5), 1122-1131.
- 598 40. Haschke, M.; Schuster, M.; Poglitsch, M.; Loibner, H.; Salzberg, M.; Bruggisser, M.; Penninger, J.;
599 Krähenbühl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-
600 converting enzyme 2 in healthy human subjects. *Clin Pharmacokinet* **2013**, 52, (9), 783-92.
- 601 41. Guo, Z.; Poglitsch, M.; McWhinney, B. C.; Ungerer, J. P. J.; Ahmed, A. H.; Gordon, R. D.; Wolley,
602 M.; Stowasser, M., Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary
603 Aldosteronism. *Clin Chem* **2020**, 66, (3), 483-492.
- 604 42. Bernstone, L.; Adaway, J. E.; Keevil, B. G., An LC-MS/MS assay for analysis of equilibrium
605 angiotensin II in human serum. *Ann Clin Biochem* **2021**, 45632211008923.
- 606 43. Basu, R.; Poglitsch, M.; Yogasundaram, H.; Thomas, J.; Rowe, B. H.; Oudit, G. Y., Roles of
607 Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. *J Am Coll Cardiol* **2017**, 69,
608 (7), 805-819.
- 609 44. van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Mels, C.; Kruger, R.; Malan, L.; Botha, S.;
610 Lammertyn, L.; Gafane, L.; Schutte, A. E., Quantification of systemic renin-angiotensin system
611 peptides of hypertensive black and white African men established from the RAS-Fingerprint(R). *J*
612 *Renin Angiotensin Aldosterone Syst* **2016**, 17, (4).
- 613 45. van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Gafane-Matemane, L. F.; Breet, Y.; Malan, L., A
614 primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in
615 black men: the SABPA study. *Cardiovasc J Afr* **2020**, 31, (3), 130-135.
- 616 46. Gafane-Matemane, L. F.; Mokae, N. L.; Breet, Y.; Poglitsch, M.; Schutte, A. E., Associations of
617 central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy
618 young adults: the African-PREDICT study. *Hypertens Res* **2021**, 44, (4), 435-445.
- 619 47. Wang, K.; Basu, R.; Poglitsch, M.; Bakal, J. A.; Oudit, G. Y., Elevated Angiotensin 1-7/Angiotensin
620 II Ratio Predicts Favorable Outcomes in Patients With Heart Failure. *Circ Heart Fail* **2020**, 13, (7),
621 e006939.
- 622 48. Reindl-Schwaighofer, R.; Hödlmoser, S.; Eskandary, F.; Poglitsch, M.; Bonderman, D.; Strassl, R.;
623 Aberle, J. H.; Oberbauer, R.; Zoufaly, A.; Hecking, M., Angiotensin-Converting Enzyme 2 (ACE2)
624 Elevation in Severe COVID-19. *Am J Respir Crit Care Med* **2021**.
- 625 49. Krenn, K.; Hobart, P.; Poglitsch, M.; Croize, A.; Ullrich, R., Equilibrium Angiotensin Metabolite
626 Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin-Converting
627 Enzyme Inhibition. *Am J Respir Crit Care Med* **2020**, 202, (10), 1468-1471.
- 628 50. Antlanger, M.; Bernhofer, S.; Kovarik, J. J.; Kopecky, C.; Kaltenecker, C. C.; Domenig, O.;
629 Poglitsch, M.; Saemann, M. D., Effects of direct renin inhibition versus angiotensin II receptor
630 blockade on angiotensin profiles in non-diabetic chronic kidney disease. *Ann Med* **2017**, 49, (6),
631 525-533.
- 632 51. Hartl, L.; Rumpf, B.; Domenig, O.; Simbrunner, B.; Paternostro, R.; Jachs, M.; Poglitsch, M.;
633 Marculescu, R.; Trauner, M.; Reindl-Schwaighofer, R.; Hecking, M.; Mandorfer, M.; Reiberger, T.,

- 634 The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis,
635 linked to endothelial dysfunction and inflammation. *Sci Rep* **2023**, 13, (1), 953.
- 636 52. Langer, B.; Grima, M.; Coquard, C.; Bader, A. M.; Schlaeder, G.; Imbs, J. L., Plasma active renin,
637 angiotensin I, and angiotensin II during pregnancy and in preeclampsia. *Obstet Gynecol* **1998**, 91,
638 (2), 196-202.
- 639 53. Wiegel, R. E.; Jan Danser, A. H.; Steegers-Theunissen, R. P. M.; Laven, J. S. E.; Willemsen, S. P.;
640 Baker, V. L.; Steegers, E. A. P.; von Versen-Hoyneck, F., Determinants of Maternal Renin-
641 Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts. *J Clin*
642 *Endocrinol Metab* **2020**, 105, (11).
- 643 54. Salas, S. P.; Marshall, G.; Gutierrez, B. L.; Rosso, P., Time course of maternal plasma volume and
644 hormonal changes in women with preeclampsia or fetal growth restriction. *Hypertension* **2006**,
645 47, (2), 203-8.
- 646 55. Malha, L.; Sison, C. P.; Helseth, G.; Sealey, J. E.; August, P., Renin-Angiotensin-Aldosterone
647 Profiles in Pregnant Women With Chronic Hypertension. *Hypertension* **2018**, 72, (2), 417-424.
- 648 56. Satou, R.; Kobori, H.; Katsurada, A.; Miyata, K.; Navar, L. G., Quantification of intact plasma AGT
649 consisting of oxidized and reduced conformations using a modified ELISA. *Am J Physiol Renal*
650 *Physiol* **2016**, 311, (6), F1211-F1216.
- 651 57. Brown, M. A.; Nicholson, E.; Gallery, E. D., Sodium-renin-aldosterone relations in normal and
652 hypertensive pregnancy. *Br J Obstet Gynaecol* **1988**, 95, (12), 1237-46.
- 653 58. Mishra, J. S.; Gopalakrishnan, K.; Kumar, S., Pregnancy upregulates angiotensin type 2 receptor
654 expression and increases blood flow in uterine arteries of rats. *Biol Reprod* **2018**, 99, (5), 1091-
655 1099.
- 656 59. Satou, R.; Penrose, H.; Navar, L. G., Inflammation as a Regulator of the Renin-Angiotensin
657 System and Blood Pressure. *Curr Hypertens Rep* **2018**, 20, (12), 100.
- 658 60. Li, X. C.; Leite, A. P. O.; Zheng, X.; Zhao, C.; Chen, X.; Zhang, L.; Zhou, X.; Rubera, I.; Tauc, M.;
659 Zhuo, J. L., Proximal Tubule-Specific Deletion of Angiotensin II Type 1a Receptors in the Kidney
660 Attenuates Circulating and Intratubular Angiotensin II-Induced Hypertension in PT-Agtr1a(-/-)
661 Mice. *Hypertension* **2021**, 77, (4), 1285-1298.
- 662 61. Brown, M. A.; Thou, S. T.; Whitworth, J. A., Stimulation of aldosterone by ACTH in normal and
663 hypertensive pregnancy. *Am J Hypertens* **1995**, 8, (3), 260-7.
- 664 62. Gennari-Moser, C.; Khankin, E. V.; Escher, G.; Burkhard, F.; Frey, B. M.; Karumanchi, S. A.; Frey,
665 F. J.; Mohaupt, M. G., Vascular endothelial growth factor-A and aldosterone: relevance to
666 normal pregnancy and preeclampsia. *Hypertension* **2013**, 61, (5), 1111-7.
- 667 63. Siddiqui, A. H.; Irani, R. A.; Zhang, W.; Wang, W.; Blackwell, S. C.; Kellems, R. E.; Xia, Y.,
668 Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1
669 induction contributes to impaired adrenal vasculature and decreased aldosterone production in
670 preeclampsia. *Hypertension* **2013**, 61, (2), 472-9.
- 671 64. Marino, G. I.; Kotsias, B. A., Expression of the epithelial sodium channel sensitive to amiloride
672 (ENaC) in normal and preeclamptic human placenta. *Placenta* **2013**, 34, (2), 197-200.
- 673 65. Escher, G.; Cristiano, M.; Causevic, M.; Baumann, M.; Frey, F. J.; Surbek, D.; Mohaupt, M. G.,
674 High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome. *Nephrol Dial Transplant*
675 **2009**, 24, (6), 1870-5.
- 676 66. Brosnihan, K. B.; Neves, L. A.; Anton, L.; Joyner, J.; Valdes, G.; Merrill, D. C., Enhanced expression
677 of Ang-(1-7) during pregnancy. *Braz J Med Biol Res* **2004**, 37, (8), 1255-62.
- 678 67. Rehan, M.; Raizman, J. E.; Cavalier, E.; Don-Wauchope, A. C.; Holmes, D. T., Laboratory
679 challenges in primary aldosteronism screening and diagnosis. *Clin Biochem* **2015**, 48, (6), 377-87.
- 680 68. Webster, L. M.; Gill, C.; Seed, P. T.; Bramham, K.; Wiesender, C.; Nelson-Piercy, C.; Myers, J. E.;
681 Chappell, L. C., Chronic hypertension in pregnancy: impact of ethnicity and superimposed

- 682 preeclampsia on placental, endothelial, and renal biomarkers. *Am J Physiol Regul Integr Comp*
683 *Physiol* **2018**, 315, (1), R36-R47.
- 684 69. Chappell, M. C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and
685 absolute? *Am J Physiol Heart Circ Physiol* **2016**, 310, (2), H137-52.
- 686 70. Chappell, M. C.; Pirro, N. T.; South, A. M.; Gwathmey, T. M., Concerns on the Specificity of
687 Commercial ELISAs for the Measurement of Angiotensin (1-7) and Angiotensin II in Human
688 Plasma. *Hypertension* **2021**, 77, (3), e29-e31.
- 689 71. Park, B. M.; Li, W.; Kim, S. H., Cardio-protective effects of angiotensin-(1-5) via mas receptor in
690 rats against ischemic-perfusion injury. *Peptides* **2021**, 139, 170516.
- 691 72. Delforce, S. J.; Lumbers, E. R.; Ellery, S. J.; Murthi, P.; Pringle, K. G., Dysregulation of the
692 placental renin-angiotensin system in human fetal growth restriction. *Reproduction* **2019**, 158,
693 (3), 237-245.
- 694 73. Gennari-Moser, C.; Escher, G.; Kramer, S.; Dick, B.; Eisele, N.; Baumann, M.; Raio, L.; Frey, F. J.;
695 Surbek, D.; Mohaupt, M. G., Normotensive blood pressure in pregnancy: the role of salt and
696 aldosterone. *Hypertension* **2014**, 63, (2), 362-8.
- 697